JP2019501202A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019501202A5 JP2019501202A5 JP2018535880A JP2018535880A JP2019501202A5 JP 2019501202 A5 JP2019501202 A5 JP 2019501202A5 JP 2018535880 A JP2018535880 A JP 2018535880A JP 2018535880 A JP2018535880 A JP 2018535880A JP 2019501202 A5 JP2019501202 A5 JP 2019501202A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitors
- inhibitor
- reverse transcriptase
- capsid
- immunostimulants
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003112 inhibitor Substances 0.000 claims 224
- 108091036055 CccDNA Proteins 0.000 claims 114
- 230000015572 biosynthetic process Effects 0.000 claims 114
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims 110
- 230000028327 secretion Effects 0.000 claims 108
- 230000003308 immunostimulating effect Effects 0.000 claims 106
- 229960001438 immunostimulant agent Drugs 0.000 claims 102
- 239000003022 immunostimulating agent Substances 0.000 claims 102
- 229940124765 capsid inhibitor Drugs 0.000 claims 100
- 208000002672 hepatitis B Diseases 0.000 claims 55
- 230000008685 targeting Effects 0.000 claims 54
- 239000002773 nucleotide Substances 0.000 claims 52
- 125000003729 nucleotide group Chemical group 0.000 claims 52
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- -1 Capsid inhibitors Substances 0.000 claims 12
- 229940079593 drug Drugs 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 8
- 108020004459 Small interfering RNA Proteins 0.000 claims 7
- 239000003795 chemical substances by application Substances 0.000 claims 4
- PBAWFYZFSXYUOS-UHFFFAOYSA-N 3-(azepan-1-ylsulfonyl)-n-benzyl-4-chlorobenzamide Chemical compound ClC1=CC=C(C(=O)NCC=2C=CC=CC=2)C=C1S(=O)(=O)N1CCCCCC1 PBAWFYZFSXYUOS-UHFFFAOYSA-N 0.000 claims 2
- 101150103227 IFN gene Proteins 0.000 claims 2
- 108010050904 Interferons Proteins 0.000 claims 2
- 102000014150 Interferons Human genes 0.000 claims 2
- 102000015696 Interleukins Human genes 0.000 claims 2
- 108010063738 Interleukins Proteins 0.000 claims 2
- 229960001997 adefovir Drugs 0.000 claims 2
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 229960000980 entecavir Drugs 0.000 claims 2
- YXPVEXCTPGULBZ-WQYNNSOESA-N entecavir hydrate Chemical compound O.C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)C1=C YXPVEXCTPGULBZ-WQYNNSOESA-N 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- 229960001627 lamivudine Drugs 0.000 claims 2
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims 2
- 230000004936 stimulating effect Effects 0.000 claims 2
- 229960004556 tenofovir Drugs 0.000 claims 2
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022065611A JP2022087209A (ja) | 2016-01-08 | 2022-04-12 | Ｂ型肝炎を治療するための治療用組成物及び方法 |
| JP2024076451A JP2024105468A (ja) | 2016-01-08 | 2024-05-09 | Ｂ型肝炎を治療するための治療用組成物及び方法 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662276722P | 2016-01-08 | 2016-01-08 | |
| US62/276,722 | 2016-01-08 | ||
| US201662343514P | 2016-05-31 | 2016-05-31 | |
| US62/343,514 | 2016-05-31 | ||
| US201662345476P | 2016-06-03 | 2016-06-03 | |
| US62/345,476 | 2016-06-03 | ||
| US201662409180P | 2016-10-17 | 2016-10-17 | |
| US62/409,180 | 2016-10-17 | ||
| US201662420969P | 2016-11-11 | 2016-11-11 | |
| US62/420,969 | 2016-11-11 | ||
| PCT/US2017/012614 WO2017120527A2 (en) | 2016-01-08 | 2017-01-06 | Therapeutic compositions and methods for treating hepatitis b |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022065611A Division JP2022087209A (ja) | 2016-01-08 | 2022-04-12 | Ｂ型肝炎を治療するための治療用組成物及び方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019501202A JP2019501202A (ja) | 2019-01-17 |
| JP2019501202A5 true JP2019501202A5 (OSRAM) | 2020-02-20 |
Family
ID=59274445
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018535880A Pending JP2019501202A (ja) | 2016-01-08 | 2017-01-06 | Ｂ型肝炎を治療するための治療用組成物及び方法 |
| JP2022065611A Pending JP2022087209A (ja) | 2016-01-08 | 2022-04-12 | Ｂ型肝炎を治療するための治療用組成物及び方法 |
| JP2024076451A Pending JP2024105468A (ja) | 2016-01-08 | 2024-05-09 | Ｂ型肝炎を治療するための治療用組成物及び方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022065611A Pending JP2022087209A (ja) | 2016-01-08 | 2022-04-12 | Ｂ型肝炎を治療するための治療用組成物及び方法 |
| JP2024076451A Pending JP2024105468A (ja) | 2016-01-08 | 2024-05-09 | Ｂ型肝炎を治療するための治療用組成物及び方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20190282604A1 (OSRAM) |
| EP (1) | EP3400008A4 (OSRAM) |
| JP (3) | JP2019501202A (OSRAM) |
| KR (2) | KR20180120675A (OSRAM) |
| CN (1) | CN110022895A (OSRAM) |
| AU (3) | AU2017205650A1 (OSRAM) |
| BR (1) | BR112018013928A2 (OSRAM) |
| CA (1) | CA3009996A1 (OSRAM) |
| CL (2) | CL2018001858A1 (OSRAM) |
| CO (1) | CO2018008249A2 (OSRAM) |
| HK (1) | HK1255835A1 (OSRAM) |
| IL (2) | IL295692A (OSRAM) |
| PH (1) | PH12018501455A1 (OSRAM) |
| SG (2) | SG11201805729SA (OSRAM) |
| TW (4) | TW202435851A (OSRAM) |
| WO (1) | WO2017120527A2 (OSRAM) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019300324A1 (en) | 2018-07-13 | 2021-01-21 | F. Hoffmann-La Roche Ag | Oligonucleotides for modulating RTEL1 expression |
| AU2020259482A1 (en) * | 2019-04-18 | 2021-10-14 | Janssen Pharmaceuticals, Inc. | Combination therapy for treating Hepatitis B Virus infection |
| WO2020214974A1 (en) * | 2019-04-18 | 2020-10-22 | Janssen Pharmaceuticals, Inc. | Combination therapy for treating hepatitis b virus infection |
| EP4081217A1 (en) * | 2019-12-24 | 2022-11-02 | F. Hoffmann-La Roche AG | Pharmaceutical combination of antiviral agents targeting hbv and/or an immune modulator for treatment of hbv |
| EP4151221A4 (en) * | 2020-05-15 | 2023-11-15 | Fujian Akeylink Biotechnology Co., Ltd. | COMBINATION COMPRISING A TRICYCLIC COMPOUND AND ITS USE IN THE PREPARATION OF A DRUG FOR THE TREATMENT OF HBV |
| US20250228818A1 (en) * | 2021-10-08 | 2025-07-17 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Pharmaceutical combination containing capsid protein inhibitor and reverse transcriptase inhibitor |
| CN117771361B (zh) * | 2024-02-27 | 2024-06-07 | 天津中逸安健生物科技有限公司 | 一种聚肌苷酸-聚胞苷酸复合物的脂质纳米佐剂及其制备方法与应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU762125B2 (en) * | 1998-02-12 | 2003-06-19 | G.D. Searle & Co. | Use of (N)-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating hepatitis virus infections |
| EP2318031A4 (en) * | 2008-06-03 | 2012-09-12 | Aethlon Medical Inc | IMPROVED METHODS AND DEVICES FOR ANTIVIRAL THERAPY |
| RU2624045C2 (ru) * | 2010-08-17 | 2017-06-30 | Сирна Терапьютикс,Инк | ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК) |
| WO2014165128A2 (en) * | 2013-03-12 | 2014-10-09 | Novira Therapeutics, Inc. | Hepatitis b antiviral agents |
| WO2015172128A1 (en) * | 2014-05-09 | 2015-11-12 | Indiana University Research And Technology Corporation | Methods and compositions for treating hepatitis b virus infections |
| US10550084B2 (en) * | 2017-12-04 | 2020-02-04 | Arbutus Biopharma Corporation | Substituted 1-hydroxy-pyridin-2(1H)-ones, and methods of making and using same |
| US10358447B2 (en) * | 2017-12-04 | 2019-07-23 | Arbutus Biopharma Corporation | Substituted 2-N-hydroxy-1,3-dioxo-1,2,3,4-tetrahydronaphthyridines, and methods of making and using same |
-
2017
- 2017-01-06 WO PCT/US2017/012614 patent/WO2017120527A2/en not_active Ceased
- 2017-01-06 BR BR112018013928A patent/BR112018013928A2/pt unknown
- 2017-01-06 CA CA3009996A patent/CA3009996A1/en active Pending
- 2017-01-06 KR KR1020187022434A patent/KR20180120675A/ko not_active Ceased
- 2017-01-06 AU AU2017205650A patent/AU2017205650A1/en not_active Abandoned
- 2017-01-06 JP JP2018535880A patent/JP2019501202A/ja active Pending
- 2017-01-06 HK HK18114911.7A patent/HK1255835A1/zh unknown
- 2017-01-06 IL IL295692A patent/IL295692A/en unknown
- 2017-01-06 IL IL303754A patent/IL303754A/en unknown
- 2017-01-06 US US16/068,243 patent/US20190282604A1/en not_active Abandoned
- 2017-01-06 SG SG11201805729SA patent/SG11201805729SA/en unknown
- 2017-01-06 SG SG10201912314QA patent/SG10201912314QA/en unknown
- 2017-01-06 KR KR1020257018649A patent/KR20250089561A/ko active Pending
- 2017-01-06 EP EP17736471.8A patent/EP3400008A4/en not_active Withdrawn
- 2017-01-06 CN CN201780014167.5A patent/CN110022895A/zh active Pending
- 2017-01-09 TW TW112146636A patent/TW202435851A/zh unknown
- 2017-01-09 TW TW111130283A patent/TW202322791A/zh unknown
- 2017-01-09 TW TW110121989A patent/TW202211912A/zh unknown
- 2017-01-09 TW TW106100606A patent/TW201735950A/zh unknown
-
2018
- 2018-07-06 CL CL2018001858A patent/CL2018001858A1/es unknown
- 2018-07-06 PH PH12018501455A patent/PH12018501455A1/en unknown
- 2018-08-03 CO CONC2018/0008249A patent/CO2018008249A2/es unknown
-
2022
- 2022-04-12 JP JP2022065611A patent/JP2022087209A/ja active Pending
- 2022-06-02 AU AU2022203814A patent/AU2022203814A1/en not_active Abandoned
- 2022-11-29 US US18/071,353 patent/US20240050463A1/en active Pending
-
2023
- 2023-03-28 CL CL2023000892A patent/CL2023000892A1/es unknown
-
2024
- 2024-05-09 JP JP2024076451A patent/JP2024105468A/ja active Pending
-
2025
- 2025-08-14 AU AU2025217340A patent/AU2025217340A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019501202A5 (OSRAM) | ||
| Nilsson-Payant et al. | The NF-κB transcriptional footprint is essential for SARS-CoV-2 replication | |
| Ouyang et al. | lncRNAs regulate the innate immune response to viral infection | |
| JP2016531144A5 (OSRAM) | ||
| JP2019068829A5 (OSRAM) | ||
| ZA202106848B (en) | 2'-substituted-n6-substituted purine nucleotides for rna virus treatment | |
| JP2020176156A (ja) | Ｔｏｌｌ様受容体モジュレーターの固体形態 | |
| IL295692A (en) | Medical preparations and methods for treating jaundice b | |
| WO2017019891A3 (en) | Compositions and methods for silencing hepatitis b virus gene expression | |
| CY1106207T1 (el) | Αντιιικα παραγωγα νουκλεοζιτων | |
| GEP20217282B (en) | β-D-2'-DEOXY-2'α-FLUORO-2'-β-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | |
| PH12021550287A1 (en) | HEPATITIS B VIRUS (HBV) dsRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | |
| JP2019530462A5 (OSRAM) | ||
| JP2018507877A5 (OSRAM) | ||
| JP2017036288A5 (OSRAM) | ||
| JP2017536344A5 (OSRAM) | ||
| JP2016128507A5 (OSRAM) | ||
| JP2014177455A5 (OSRAM) | ||
| WO2010081082A3 (en) | Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections | |
| JP2016508134A5 (OSRAM) | ||
| CY1109012T1 (el) | Παραγωγα νουκλεοσιδιου σαν αναστολεις της rna-εξαρτωμενης rna iϊκης πολυμepασης | |
| JP2019525905A5 (OSRAM) | ||
| JP2017521433A5 (OSRAM) | ||
| EA201000085A1 (ru) | dsPHK, ПРЕДНАЗНАЧЕННАЯ ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ИНФЕКЦИИ | |
| JOP20210249A1 (ar) | مشتقات البيرميدون الحلقية المدمجة للاستخدام في علاج عدوىhbv أو الأمراض التي يسببها فيروس hbv |